MeiraGTx Holdings plc Retained Earnings
MeiraGTx Holdings plc (MGTX) had Retained Earnings of -$701.82 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$701.82M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$862.54M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$816.22M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$831.31M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$701.82M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | -$862.54M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | -$816.22M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | -$831.31M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$780.80M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | -$742.00M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | -$702.02M 10-K · filed 2026-03-30 | |
| 2024-09-30 | -$662.62M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | -$623.29M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | -$574.67M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | -$554.23M 10-K · filed 2025-03-13 | |
| 2023-09-30 | -$574.45M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | -$530.15M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | -$500.57M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | -$470.20M 10-K · filed 2024-03-15 | |
| 2022-09-30 | -$442.89M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | -$405.61M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | -$371.63M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | -$340.59M 10-K · filed 2023-03-14 | |
| 2021-09-30 | -$330.68M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | -$304.73M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | -$284.64M 10-Q · filed 2021-05-11 | |
| 2020-12-31 | -$261.03M 10-K · filed 2022-03-10 | -$261.03M 10-K · filed 2021-03-11 |
| 2020-09-30 | -$250.57M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | -$244.14M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | -$218.72M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | -$203.04M 10-K · filed 2021-03-11 | |
| 2019-09-30 | -$197.55M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | -$187.09M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | -$166.27M 10-Q · filed 2019-05-14 | |
| 2018-12-31 | -$148.29M 10-K · filed 2020-03-11 | |
| 2018-09-30 | -$127.23M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | -$111.81M 10-Q · filed 2018-08-08 | |
| 2017-12-31 | -$65.42M 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |